Syros Pharmaceuticals completed a new $53 million equity offering

syros Syros Pharmaceuticals sold a total of $53.15 million in a non-brokered equity investment round. The transaction which started on October 9th, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $13.25 million.

Syros Pharmaceuticals develops a proprietary platform that identifies the master switches for disease genes, opening a new approach to novel therapeutics. The company’s initial focus is on cancer, but the platform will also be applicable to other therapeutic areas. Investors include ARCH Venture Partners and Flagship Ventures.

The company, headquartered in Watertown MA, is led by Nancy Simonian (CEO). Syros Pharmaceuticals elected to keep its revenues undisclosed.
The executive team includes Jorge Conde.
The board of directors includes Douglas Cole, James E Bradner, Philip Sharp, Richard A Young, Robert Nelsen, Stephane Bancel and Vicki Sato.

The company has raised an estimated total of $66.4 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Syros Pharmaceuticals
Industry: Biotechnology
Amount offered: $53.15 million
Amount placed: $53.15 million
First sale: 10-09-2014
Data as of: 10-24-2014

For more information visit


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s